| 摘要 |
<p>Agent for treating bone loss disorders, an agent to enhance osteogenesis, and an agent to increase the bone amount of cortical bone, each contain (1) a material which inhibits osteopontinin vivo; and (2) at least one of parathyroid hormone (PTH), PTH derivative and PTH receptor agonist. ACTIVITY : Osteopathic. Mice, and osteopontin knock-out mice of the same strain, were given 80 Microg/kg of human PTH subcutaneously, 5 days a week for 4 weeks. Cortical bone thickness was 0.26 mm for the PHT-treated knock-out mice (0.20 for the normal mice) compared with 0.20 for untreated mice (0.18 for the normal untreated mice). MECHANISM OF ACTION : None given.</p> |
